Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elritercept in Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy
NCT07623161Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 31
01
Overview
A Phase 3 trial of elritercept in myelofibrosis (MF), anemia, sponsored by Takeda. Started Sep 2026; status: recruiting.
02
Drugs
elritercept
03
Conditions
myelofibrosis (MF)anemia
Beyond the preview
Go deeper on NCT07623161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623161.